Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Drug Targets|June 21, 2003
Hepatoma derived growth factor is a nuclear targeted mitogenAllen D Everett, John Bushweller
Advances in Experimental Medicine and Biology|March 17, 2017
Structure and Biophysics of CBFβ/RUNX and Its Translocation ProductsTahir H Tahirov, John Bushweller
International Journal of Cancer|December 28, 2024
FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progressionMaría S Rodriguez, Yamil D Mahmoud, Silvia Vanzulli, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
The MLLT3 YEATS domain is a dual reader of histone marks (H3K9/18/27ac/cr) and ncRNA (7SK), linking epigenetic and RNA signaling to regulate hematopoiesisAdam Boulton, Ashish Kabra, Nicholas Achille, et al.
Cancer Cell|May 19, 2010
Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1Yasuhiko Kamikubo, Ling Zhao, Mark Wunderlich, et al.
Cell Reports|December 17, 2023
Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growthDaniel J L Coleman, Peter Keane, Rosario Luque-Martin, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growthDaniel J L Coleman, Peter Keane, Rosario Luque-Martin, et al.
Iscience|April 19, 2024
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1Daniel J L Coleman, Peter Keane, Paulynn S Chin, et al.
Journal of Cellular Physiology|March 18, 2020
RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cellsAndrew J Fritz, Deli Hong, Joseph Boyd, et al.
Pageof 1